



CONTENTS

From the editor's desk

GLOBAL NEWS

- Intas acquires UK and Irish assets of Teva Pharma for \$1 bn
- India and Africa to team up in medical research
- Study looks into risk factors that may contribute to nonunion of fractures
- INSIGHTMM: Antibiotics in the first year of kids maybe linked to increased risk for developing food allergy
- A new global observational study in multiple myeloma by Takeda
- Will China and India join the ICH and pharmaceutical inspection co-operation scheme?

PHARMA INDIA

- Strong growth seen by Indian pharmaceutical
- Validity of approval of BA/BE centres and bioanalytical labs: Extended from 1 year to 3 years by DCGI
- 500 drug inspectors to be recruited by CDSCO: To enhance cGMP compliance

REGULATORY ROUNDUP

- Manufacturers to check GMP, GLP compliance as per DCGI orders
- Boxed warning on two drug classes: Opioids and benzodiazep
- BWG, an international biosimilars working group, proposes principles for indication extrapolation
- OPDP and RTI International: Cancer drug websites provide more information on benefits than risks
- DCGI plans to ban several FDCs approved by SLAs

MERGERS /ACQUISITIONS /COLLABORATIONS

- Omecamtiv Mecarbil collaboration extended by Amgen and Servier
- PPD completes the acquisition of Evidera
- Sanofi and Verily Life Sciences launch Onduo: Collaboration to develop diabetes management platform
- Aspen to buy GSK's anesthetics portfolio

DRUGS: APPROVALS & LAUNCHES

- Sandoz's Enbrel's bisomilar approved in the US
- Ofatumumab with chemo has been approved by the US FDA for relapsed CLL



From the editor's desk

Announcing the Launch of Our Redesigned Newsletter

Dear All,

It is said that change is the only constant in life. That's certainly true for our editors here, who have worked tirelessly to develop the new aesthetic, simplified and easy accessible design of Lambda Clinical Research Newsletter.

With the October issue, I am pleased to announce the redesign of our newsletter; it will be published as an e-Newsletter, the first issue of which we are releasing this month. The newsletter will contain information of interest to our users categorized into different sections including Global News, Pharma India, Regulatory Round-Up, Drugs Approvals and Launches, Drugs in Development and Clinical Trials, Merger/ Acquisition/ Collaborations and Patents and Technology related news.

We have tried to include more information that may help you gain more knowledge regarding the news items which is the major change in content from our previous newsletter.

Our goal with this newsletter is to create something that is candid, genuine and beneficial to our customers in their fast lives and which will eventually facilitate as a channel between us and our growing customer community.

I appreciate you taking the time to read the newsletter and look forward for your views. Your feedback is very important to us as we strive to develop a newsletter that is valuable to you.

If you are interested in contributing, please let us know

medicalintelligence@lambda-cro.com

Dr. Tausif Monif
President - Global operations

Contact Us

- **Dr. Tausif Monif**
President - Global operations
Tausifmonif@lambda-cro.com
- **Dr. Mrinal Kammili**
Ex. Director – Global Head, BD
mrinal@lambda-cro.com

Disclaimer: "The information compiled and published in this newsletter have been collected from various public domain resources available on web and relevant magazines. The Public Domain information is not confidential and may be freely distributed and copied. However, transmission or reproduction of protected items beyond that allowed by fair use

- FDA approves Heron Therapeutics' Sustol(granisetron) extended-release injection

DRUGS: DEVELOPMENT & CLINICAL TRIALS

- initiates Phase III trial of dengue vaccine
- Top line results from Phase III Prolia study
- SAGE-547 for postpartum depression: Breakthrough designation from FDA
- Nintedanib granted Orphan Drug Designation
- Sotagliflozin's Phase III top-line results: Meets endpoint

PATENTS: NEW APPROVALS /LITIGATIONS /SETTLEMENTS

- Apobiologix and Amgen dispute: Court rules in favour of Apobiologix
- New composition of matter patent has been granted for dusquetide analogs

TECHNOLOGY/ NDDS NEWS

- Blood test to predict Alzheimer's disease ?
- New protein iCas can alter DNA in living cells: Singapore researchers
- Antibiotic gel to manage ear infections: Promising results from preclinical research

as defined in the copyright laws requires the written permission of the copyright owners, if any. Lambda directly or indirectly shall not be responsible for any legal/ethical litigation claimed by any professional agency / bodies."